Table 2.

Detailed analysis of influence of reTURB timing on oncological outcomes

Clinical event	Group (TTBCG intervals, weeks)	HR	CI95%	pvalue
Recurrence	6–10	1.00	Ref.
	11–14	1.14	(0.70.1.86)	0.590
	15–18	1.54	(0.94.2.50)	0.084
	19–25	1.62	(1.02.2.58)	0.041
Progression	6–10	1.00	Ref.
	11–14	1.94	(0.78.4.81)	0.152
	15–18	3.15	(1.32.7.55)	0.010
	19–25	3.34	(1.42.7.81)	0.005

The value of adjusted p < 0.05 was considered statistically significant (bolded)

HR Hazard ratio, TTBCG time to BCG, 95%CI 95% confidence interval